About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Two Strategies for Reducing Mortality in HIV Immunosuppressed Adults

by Hannah Joy on March 6, 2018 at 11:28 AM
Two Strategies for Reducing Mortality in HIV Immunosuppressed Adults

Two innovative strategies have been designed that can reduce mortality in severely immunosuppressed HIV-infected adults.

The STATIS trial (sponsor Inserm-ANRS) was coordinated by Professors François-Xavier Blanc (CHU de Nantes) and Serge Domoua (Programme PAC-CI, CHU de Treichville, Abidjan), the trial is being conducted in Cambodia, Côte d'Ivoire, Uganda, and Vietnam.

Advertisement


The results were presented at the Conference on Retroviruses and Opportunistic Infections held in Boston.

Despite increased access to HIV screening and antiretroviral therapy, many HIV-infected people still enter healthcare systems very late, by which time severe immunosuppression complicates management.
Advertisement

Mortality is high in these patients, notably because of tuberculosis, the leading cause of death in HIV-infected people. Patients who initiate antiretroviral therapy late are currently offered simple tuberculosis screening.

The STATIS trial (sponsor Inserm-ANRS) has studied the effects of intensive, systematic, and continuous screening for tuberculosis compared with systematic use of antituberculosis therapy on mortality in these patients.

The first results of this study, which is conducted by Professors François-Xavier Blanc (CHU de Nantes) and Serge Domoua (Programme PAC-CI, CHU de Treichville, Abidjan) and their colleagues in Cambodia, Côte d'Ivoire, Uganda, and Vietnam, will be disclosed in an oral presentation at the Conference on Retroviruses and Opportunistic Infections (CROI 2018).

The study analyzed data from 1047 adult patients who had never received antiretroviral therapy and whose CD4+ cell count was low (<100/mm3) at inclusion. At initiation of antiretroviral therapy, these patients were randomized between two arms.

In the first arm, the patients underwent tuberculosis screening comprising an Xpert MTB/RIF test and a urine lipoarabinomannan assay.

Only patients who tested positive were then given antituberculosis drugs. The tests could be repeated throughout follow-up, depending on symptoms.

In the second arm, all patients received systematic antituberculosis therapy.

The success rates of these two strategies, as a function of the number of deaths or of invasive bacterial infections during the first 24 weeks of follow-up, were higher than that previously reported in the literature for simple tuberculosis screening.

There was no significant difference between the two strategies.

ANRS STATIS therefore shows that systematic initiation of antituberculosis treatment is no superior than intensive tuberculosis screening in reducing mortality in severely immunosuppressed HIV-infected adults when they enter the healthcare system.

The study is still ongoing and new analyses will be performed for each patient after 48 weeks of follow-up. The two strategies compared in this study are particularly suited to resource-limited settings.



Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest AIDS/HIV News

HIV Vaccine Clinical Trial Initiates in the United States and South Africa
The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.
Beauty Salon-Driven Initiative Boosts PrEP Awareness in Fight Against AIDS
In the United States, African American women make up only 26% of female PrEP users, yet they account for 57% of new infections among women.
Immune-Evading HIV Protein Complex Solved
Scientists have made a groundbreaking discovery in the fight against HIV/AIDS with the successful resolution of the enigmatic immune-evading HIV protein complex.
Does Gender Influence Comorbidity Rates in HIV-Positive Smokers
Tailored quit-smoking programs are designed to address the risks associated with comorbidity in individuals living with HIV.
Digital Test Measures HIV Viral Load
DNA editing tool CRISPR-Cas13 helps diagnose and signal the presence of HIV antibodies in HIV patients.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

Two Strategies for Reducing Mortality in HIV Immunosuppressed Adults Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests